Found 5 Renal Cancer trials

A listing of Renal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 18822: Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma

99 years and younger

All genders

Please refer to Protocol Section 3.0. Please refer to Protocol Section 3.1. Please refer to Protocol Section 3.2.

Learn More

UPCC 25823 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

99 years and younger

All genders

This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. We would like to rely on WCG …

Learn More

UPCC 05823: Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

99 years and younger

All genders

To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma. We would like to rely on WCG as the IRB of record for this study.

Learn More

UPCC 13824: A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma

99 years and younger

All genders

The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS. We would like to rely …

Learn More

EMBARC

99 years and younger

All genders

The dual primary objectives of the study are: 1) to estimate the safety of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma, and 2) to estimate the feasibility of patient enrollment in such a trial. The dual primary endpoints are safety, as …

Learn More